In hematological malignancies, the most commonly targeted proteins include CD19, BCMA, and CD22, whereas in solid tumors, tumor-associated antigens (TAA), HER2, and mesothelin (MSLN) are frequently targeted (15). This evidence concerns the gene ERBB2 and neoplasm.